200 related articles for article (PubMed ID: 15665803)
1. Hyperprolactinemia after low dose of amisulpride.
Kopecek M; Bares M; Svarc J; Dockery C; Horácek J
Neuro Endocrinol Lett; 2004 Dec; 25(6):419-22. PubMed ID: 15665803
[TBL] [Abstract][Full Text] [Related]
2. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
Kopecek M; Bares M; Horacek J; Mohr P
Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
[TBL] [Abstract][Full Text] [Related]
3. Amisulpride-induced hyperprolactinemia is reversible following discontinuation.
Paparrigopoulos T; Liappas J; Tzavellas E; Mourikis I; Soldatos C
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):92-6. PubMed ID: 16938372
[TBL] [Abstract][Full Text] [Related]
4. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
[TBL] [Abstract][Full Text] [Related]
5. Normalization of hyperprolactinaemia after withdrawal of a low dose of amisulpride.
Kopecek M; Bares M; Horácek J
Neuro Endocrinol Lett; 2005 Aug; 26(4):320. PubMed ID: 16136015
[No Abstract] [Full Text] [Related]
6. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
[TBL] [Abstract][Full Text] [Related]
7. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride.
Kim EY; Kim SH; Lee NY; Jung DC; Kim YS; Ahn YM
Pharmacopsychiatry; 2012 Mar; 45(2):57-63. PubMed ID: 22411694
[TBL] [Abstract][Full Text] [Related]
8. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
Chen CK; Huang YS; Ree SC; Hsiao CC
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases.
Akkaya C; Kaya B; Kotan Z; Sarandol A; Ersoy C; Kirli S
J Psychopharmacol; 2009 Aug; 23(6):723-6. PubMed ID: 18562408
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report.
Bliesener N; Yokusoglu H; Quednow BB; Klingmüller D; Kühn KU
Pharmacopsychiatry; 2004 Jul; 37(4):189-91. PubMed ID: 15467977
[No Abstract] [Full Text] [Related]
11. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
Bergemann N; Kopitz J; Kress KR; Frick A
Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with amisulpride and antidepressants: clinical observations in case series of elderly patients with psychotic depression.
Politis AM; Papadimitriou GN; Theleritis CG; Psarros C; Soldatos CR
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jul; 32(5):1227-30. PubMed ID: 18442877
[TBL] [Abstract][Full Text] [Related]
13. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
[TBL] [Abstract][Full Text] [Related]
14. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
[TBL] [Abstract][Full Text] [Related]
15. Hyperprolactinaemia with amisulpride.
Ružić K; Grahovac T; Graovac M; Dadić-Hero E; Sepić-Grahovac D; Sabljić V
Psychiatr Danub; 2011 Mar; 23(1):92-4. PubMed ID: 21448106
[TBL] [Abstract][Full Text] [Related]
16. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia.
Cook B; Hoogenboom G
Australas Psychiatry; 2004 Mar; 12(1):74-6. PubMed ID: 15715745
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics.
Bushe C; Shaw M
J Psychopharmacol; 2007 Sep; 21(7):768-73. PubMed ID: 17606473
[TBL] [Abstract][Full Text] [Related]
18. Is second-generation antipsychotic-induced hyperprolactinemia due to biologically active prolactin or to biologically inactive macroprolactin? Results from a prospective study.
Tschoner A; Engl J; Rettenbacher MA; Kaser S; Ott HW; Fleischhacker WW; Patsch JR; Ebenbichler CF
J Clin Psychiatry; 2009 Feb; 70(2):293-4. PubMed ID: 19265646
[No Abstract] [Full Text] [Related]
19. Low-dose amisulpride and elevation in serum prolactin.
Andrade C
J Clin Psychiatry; 2013 Jun; 74(6):e558-60. PubMed ID: 23842026
[No Abstract] [Full Text] [Related]
20. Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial.
Kim SW; Shin IS; Kim JM; Lee SH; Lee JH; Yoon BH; Yang SJ; Hwang MY; Yoon JS
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1504-9. PubMed ID: 17692448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
